Journal of Yeungnam Medical Science

영남대 의대 학술지 편집위원회 (Yeungnam University College of Medicine, Yeungnam University Institute Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Incidence and severity of medication-related osteonecrosis of the jaw in patients with osteoporosis using data from a Korean nationwide sample cohort in 2002 to 2019: a retrospective study

  • Su-Youn Ko (Gyeongsangbuk-do Public Health Policy Institute) ;
  • Tae-Yoon Hwang (Department of Preventive Medicine and Public Health, Yeungnam University College of Medicine) ;
  • Kiwook Baek (Department of Occupational and Environmental Medicine, Yeungnam University Hospital) ;
  • Chulyong Park (Department of Preventive Medicine and Public Health, Yeungnam University College of Medicine)
  • 투고 : 2023.10.18
  • 심사 : 2023.11.29
  • 발행 : 2024.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Medication-related osteonecrosis of the jaw (MRONJ) is a significant concern, particularly among patients taking bisphosphonates (BPs), denosumab, and selective estrogen receptor modulators (SERMs) for osteoporosis. Despite the known risks, large-scale cohort studies examining the incidence and severity of MRONJ are lacking. We aimed to ascertain the incidence and risk of MRONJ among these patients, whom we stratified by age groups, medication types, and duration of use. Methods: We utilized data from the National Health Insurance Service's sample cohort database, focusing on patients aged 40 years and above diagnosed with osteoporosis. The patients were divided into three groups: those prescribed BPs only, those prescribed SERMs only, and those prescribed both. Results: The overall incidence rate of MRONJ was 0.17%. A significantly higher incidence rate was observed among those taking osteoporosis medications, particularly among females with a relative risk of 4.99 (95% confidence interval, 3.21-7.74). The SERM group also had an incidence rate comparable to that of the BP group. Severity was assessed based on the invasiveness of the treatment methods, with 71.3% undergoing invasive treatment in the medication group. Conclusion: This study provides valuable insights into the incidence and severity of MRONJ among a large cohort of patients with osteoporosis. It underscores the need for comprehensive guidance on MRONJ risks across different medication groups and sets the stage for future research focusing on specific populations and treatment outcomes.

키워드

과제정보

This work was supported by 2022 Yeungnam University Research Grant (No. 222A480007).

참고문헌

  1. AlDhalaan NA, BaQais A, Al-Omar A. Medication-related osteonecrosis of the jaw: a review. Cureus 2020;12:e6944.
  2. Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol 2014;10:257-75. https://doi.org/10.2217/fon.13.211
  3. Jeon Y, Kim IJ. Pharmacological treatment of osteoporosis: 2022 update. J Korean Med Assoc 2022;65:241-8. https://doi.org/10.5124/jkma.2022.65.4.241
  4. Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int 2018;2018:2684924.
  5. Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res 2011;90:439-44. https://doi.org/10.1177/0022034510397196
  6. Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68:243-53. https://doi.org/10.1016/j.joms.2009.03.050
  7. Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, Akinyemi O, et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 2011;16:121-32. https://doi.org/10.1634/theoncologist.2010-0183
  8. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws: 2022 update. J Oral Maxillofac Surg 2022;80:920-43. https://doi.org/10.1016/j.joms.2022.02.008
  9. Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 2021;16:609.
  10. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 2012;41:1397-403. https://doi.org/10.1016/j.ijom.2012.06.020
  11. Dioguardi M, Spirito F, Alovisi M, Aiuto R, Garcovich D, Crincoli V, et al. Location and gender differences in osteonecrosis of the jaws in patients treated with antiresorptive and antineoplastic drugs undergoing dentoalveolar surgical, systematic review with meta-analysis and trial sequential analysis. J Clin Med 2023;12:3299.
  12. Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H. Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: a nationwide population-based study in Japan. J Oral Maxillofac Surg 2022;80:714-27. https://doi.org/10.1016/j.joms.2021.12.007
  13. Baur DA, Altay MA, Teich S, Schmitt Oswald M, Quereshy FA. Osteonecrosis of the jaw in a patient on raloxifene: a case report. Quintessence Int 2015;46:423-8.
  14. Bindakhil M, Shanti RM, Mupparapu M. Raloxifene-induced osteonecrosis of the jaw (MRONJ) with no exposure to bisphosphonates: clinical and radiographic findings. Quintessence Int 2021;52:258-63.
  15. Gupta M, Gupta N. Bisphosphonate related jaw osteonecrosis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Oct 5]. https://www.ncbi.nlm.nih.gov/books/NBK534771/